BASF offers a broad portfolio of functional excipients suitable for physical mixing processes.
Did you know that the role of excipients play a more relevant role to the bioavailability enhancement of a drug molecule than the process technology? Discussing drug delivery systems such as amorphous solid dispersions it is often overseen that the excipient can enhance the drug’s bioavailability often sufficiently already when not being processed by so-called enabling technologies such as hot melt extrusion or spray drying. BASF spend a significant resources in the investigation of standard processes you have in-house available such as standard dry-, wet- and melt granulation for the enhancement of a drug’s bioavailability. BASF could proof that using functional excipients such as Soluplus® in a wet granulation process could enhance the dissolution of Danazol to 80% performance compared to a corresponding melt extruded solid dispersion.
By this BASF reached a milestone as such formulation reach a sufficient bioavailability enhancement at a much better risk profile. As the drug can remain in its crystalline state, there is no risk of re-crystallisation in solid state. Furthermore there is no risk of changing dissolution profiles due to relaxation issues as they are known from amorphous solid dispersions.
Talk to us about how BASF can help you enhancing your drug’s bioavailability at a lowest possible formulation risk profile.